ArticleBioactive materials2023
Stem cell-derived hepatocyte therapy using versatile biomimetic nanozyme incorporated nanofiber-reinforced decellularized extracellular matrix hydrogels for the treatment of acute liver failure.
Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer.Bioactive materials · 2026Article
- Quadruplex Bioactive FAND for Treating Acute Liver Failure Induced by Acetaminophen or Hepatectomy.Exploration (Beijing, China) · 2026Article
- Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.Gels (Basel, Switzerland) · 2026Review
- From scaffold to function: A systematic review on dLECM-based hydrogels for liver tissue engineering - Fabrication, properties, and translational applications.Regenerative therapy · 2026Review
- [Extracellular matrix materials and tissue regeneration and repair].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Spatial patterning strategies for liver tissue engineering: Biofabrication technologies and applications.Advanced drug delivery reviews · 2026Review
- Selenium Nanoparticles-Encapsulated Exosomes That Mitigate Acute Liver Injury via an Oral Carboxymethyl Chitosan/Oxidized Dextran Hydrogel.ACS applied materials & interfaces · 2025Article
- New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).International journal of molecular medicine · 2025Review
- Stimuli-responsive hybrid materials for 4DMaterials today. Bio · 2025Review
- Mesenchymal stromal/stem cell spheroid-derived extracellular vesicles advance the therapeutic efficacy of 3D-printed vascularized artificial liver lobules in liver failure treatment.Bioactive materials · 2025Article
- Decellularized Extracellular Matrices for Skin Wound Treatment.Materials (Basel, Switzerland) · 2025Review
- Engineering a dynamic extracellular matrix using thrombospondin-1 to propel hepatocyte organoids reprogramming and improve mouse liver regeneration post-transplantation.Materials today. Bio · 2025Article
- Cascaded immunotherapy with implantable dual-drug depots sequentially releasing STING agonists and apoptosis inducers.Nature communications · 2025Article
- Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025Review
- Biomimetic Vascularized iPSC-Hepatocyte Spheroids for Liver Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ultra-small quercetin-based nanotherapeutics ameliorate acute liver failure by combatting inflammation/cellular senescence cycle.Theranostics · 2025Article
- Recent Development of Fibrous Hydrogels: Properties, Applications and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Decellularized liver scaffolds for constructing drug-metabolically functionalBioactive materials · 2025Article
- Wnt 3a-Modified Scaffolds Improve Nerve Regeneration by Boosting Schwann Cell Function.ACS applied materials & interfaces · 2024Article
- Dipeptidyl peptidase-4 marks distinct subtypes of human adipose stromal/stem cells with different hepatocyte differentiation and immunoregulatory properties.Stem cell research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS)-associated oxidative stress, inflammation storm, and massive hepatocyte necrosis are the typical manifestations of acute liver failure (ALF), therefore specific therapeutic interventions are essential for the devastating disease. Here, we developed a platform consisting of versatile biomimetic copper oxide nanozymes (Cu NZs)-loaded PLGA nanofibers (Cu NZs@PLGA nanofibers) and decellularized extracellular matrix (dECM) hydrogels for delivery of human adipose-derived mesenchymal stem/stromal cells-derived hepatocyte-like cells (hADMSCs-derived HLCs) (HLCs/Cu NZs@fiber/dECM). Cu NZs@PLGA nanofibers could conspicuously scavenge excessive ROS at the early stage of ALF, and reduce the massive accumulation of pro-inflammatory cytokines, herein efficiently preventing the deterioration of hepatocytes necrosis. Moreover, Cu NZs@PLGA nanofibers also exhibited a cytoprotection effect on the transplanted HLCs. Meanwhile, HLCs with hepatic-specific biofunctions and anti-inflammatory activity acted as a promising alternative cell source for ALF therapy. The dECM hydrogels further provided the desirable 3D environment and favorably improved the hepatic functions of HLCs. In addition, the pro-angiogenesis activity of Cu NZs@PLGA nanofibers also facilitated the integration of the whole implant with the host liver. Hence, HLCs/Cu NZs@fiber/dECM performed excellent synergistic therapeutic efficacy on ALF mice. This strategy using Cu NZs@PLGA nanofiber-reinforced dECM hydrogels for HLCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.